The goal of this clinical trial is to determine whether adding strength training to aerobic training has a comparable or greater effect on the clinical status of Parkinson's disease patients than a standalone aerobic training. \- Does combined strength-endurance circuit training provide added benefits to physical performance, disease severity, blood biomarkers, and quality of life in PD patients compared to standalone aerobic training? Participants will: * undergo outcome measurements before and after the 12-week intervention and a 3-month follow-up measurement, * visit the clinic twice a week for 1-hour training sessions. * selected patients will be given a smartwatch with a pedometer that will count their average number of steps before, during and after the training period
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
90
The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
Department of Neurology and Centre of Clinical Neuroscience First Faculty of Medicine, Charles University and General University Hospital in Prague
Prague, Prague, Czechia
RECRUITINGMovement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II. and III.
The maximum total UPDRS score is 272, indicating the worst possible disability from PD. The minimum total score is 0, indicating no disability from PD. Improvement greater than (-4.9) points or worsening more than (+4.2) points on MDS-UPDRS II+III represent a minimal clinically important difference.
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
One Repetition Maximum (1RM)
One Repetition Maximum in strength training is the maximum weight that can be lifted once while maintaining the correct lifting technique. It will be measured using a leg press machine for the lower extremities and a dumbbell chest press for the upper extremities.
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Timed Up and Go Test (TUG)
Mean TUG score for Non-falling PD patients on medication is 7.94 (2.15) seconds. MCID is 3.5 seconds.
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Blood irisin levels
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Cardiopulmonary Exercise Testing
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
The Parkinson's Disease Questionnaire (PDQ-39)
The minimum score is 0, while the maximum score is 100. A higher score indicates a lower QoL.
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Blood brain-derived neurotrophic factor levels
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Blood cytokine levels
Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)
Average number of steps
Time frame: Average number of steps in the period before training (6 months), during the training period (3 months), period after training (3 months).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.